Human Nerve Growth Factor Receptor and Cytosine Deaminase Fusion Genes
- 10 July 2003
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 14 (10) , 1009-1016
- https://doi.org/10.1089/104303403766682269
Abstract
Cytosine deaminase (CD) converts 5-fluorocytosine (5-FC) to the toxic metabolite 5-fluorouracil (5-FU), and has been investigated extensively as a potential tool for selective cellular eradication. In this paper, genetic constructs were designed to express the CD enzyme fused to the transmembrane and extracellular domains of the human nerve growth factor receptor (NGFR), thus allowing for positive identification of transduced cells by flow cytometry and positive selection by magnetic bead technology. Constructs were designed to encode a [Gly4Ser]2 flexible linker between the nucleic acid coding sequences for the NGFR and CD genes. Retroviral vectors constructed with wild-type CD and NG/CD fusion genes were used to transduce 3T3 fibroblasts and the human T cell line CEM. The function of CD fusion genes was comparable to that of wild-type genes as determined in cytotoxicity assays. By flow cytometry, the NGFR antigen was detectable after expression of the fusion gene derived from either Escherichia coli (NG/CDe) or Saccharomyces cerevisiae (NG/CDs), but the greatest antigen density was observed in cells transduced with the NG/CDs vector. Similarly, superior 5-FC sensitivity was observed with NG/CDs fusion gene in both murine fibroblasts and human T cells. In addition, CEM cells expressing NG/CDs were more efficiently eliminated in vivo. Engineering of cells utilizing the chimeric NG/CD genes provides a new modality in gene therapy allowing positive and negative selection using a single protein-coding sequence.Keywords
This publication has 24 references indexed in Scilit:
- Clinical-Scale Selection of Anti-CD3/CD28–Activated T Cells After Transduction with a Retroviral Vector Expressing Herpes Simplex Virus Thymidine Kinase and Truncated Nerve Growth Factor ReceptorHuman Gene Therapy, 2002
- Murine Leukemia Induced by Retroviral Gene MarkingScience, 2002
- Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cellsCancer Gene Therapy, 2001
- Cell Surface Tagging and a Suicide Mechanism in a Single Chimeric Human ProteinHuman Gene Therapy, 1999
- Enzyme/Prodrug Therapy for Head and Neck Cancer Using a Catalytically Superior Cytosine DeaminaseHuman Gene Therapy, 1999
- Resistance to 5-FluorouracilGeneral Pharmacology: The Vascular System, 1998
- Herpes Simplex Virus Thymidine Kinase Gene Transfer for Controlled Graft-versus-Host Disease and Graft-versus-Leukemia: Clinical Follow-up and Improved New VectorsHuman Gene Therapy, 1998
- Use of Donor T-Lymphocytes Expressing Herpes-Simplex Thymidine Kinase in Allogeneic Bone Marrow Transplantation: A Phase I–II Study. Laboratorie d'Histocompatibilité et Thérapeutique Immuno-Moléculaire, Besançon, FranceHuman Gene Therapy, 1997
- Gene Therapy for Metastatic Malignant Melanoma: Evaluation of Tolerance to Intratumoral Injection of Cells Producing Recombinant Retroviruses Carrying the Herpes Simplex Virus Type 1 Thymidine Kinase Gene, to be Followed by Ganciclovir Administration. Laboratoire Immunologie B, Hôpital Pitié-Salpêtrière, Paris Cedex, FranceHuman Gene Therapy, 1996
- Constitutive interleukin 2 production by the JURKAT human leukemic T cell lineEuropean Journal of Immunology, 1982